Breaking Finance News

Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) to Hold in a report released on 09/29/2016.

Just yesterday Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) traded -2.90% lower at $46.37. Dr.Reddy's Laboratories Ltd (ADR)’s 50-day average is $46.31 and its two hundred day average is $46.71. With the last close down -0.46% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 75,615 shares of RDY changing hands under the typical 337,897

See Chart Below

Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY)

Dr.Reddy's Laboratories Ltd (ADR) has a 52 week low of $40.67 and a 52 week high of $68.00 with a P/E ratio of 35.42 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 2 equity analysts have released a ratings update on RDY. The one year target is $44.73 with zero equity analysts rating the company a strong buy, zero firms rating the stock a buy, 1 firm rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY)

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *